Understanding RSV Vaccine Recommendations for Seniors

What RSV Is and Why It Matters for Older Adults

Respiratory Syncytial Virus, or RSV, is a common virus that most people encounter at some point in their lives. For young children, RSV typically causes cold-like symptoms that resolve on their own within a week or two. But for adults aged 60 and older, RSV can develop into something much more serious.

Learn About Finding Your Kenya Tax Number →

The virus attacks the respiratory tract—your lungs and the tubes that carry air to them. In older adults, this can lead to severe bronchiolitis (inflammation of small airways) or pneumonia. According to the Centers for Disease Control and Prevention, RSV causes an estimated 160,000 hospitalizations and 10,000 deaths annually among people aged 60 and older in the United States. To put this in perspective, that's roughly the population of a mid-sized city dealing with serious RSV complications every year.

What makes RSV particularly concerning for seniors is that older bodies mount weaker immune responses to viral infections. Combined with conditions that many seniors have—such as chronic lung disease, heart disease, or diabetes—RSV can escalate quickly from a cough and fever into a medical emergency requiring hospitalization.

The risk increases further for people living in group settings like nursing homes or assisted living facilities, where the virus spreads more easily between residents. A single RSV case in such a facility can trigger an outbreak affecting dozens of vulnerable people.

Understanding RSV and how vaccines work against it matters because prevention has become possible in ways it wasn't before 2023. Two RSV vaccines were approved by the FDA in June 2023, marking the first time public health authorities could offer vaccine protection against this virus to older adults. This represents a significant shift in how we approach RSV prevention for seniors.

Practical takeaway: RSV in seniors is not just a cold—it's a virus that sends thousands to hospitals annually. Knowing the difference between RSV and typical cold symptoms helps you understand why health providers now discuss this vaccine with older patients.

The Two RSV Vaccines: How They Differ

Two distinct RSV vaccines are now available for people aged 60 and older: Arexvy (made by GlaxoSmithKline) and Abrysvo (made by Pfizer). While both target the same virus and are given as a single dose, they use different manufacturing approaches and have slightly different characteristics that matter when considering which one might be recommended to you.

Learn About Treating Eye Styes at Home →

Arexvy uses a protein-based technology. This means the vaccine contains a piece of the RSV virus that has been manufactured in a laboratory, rather than the virus itself or genetic instructions to make viral proteins. The protein included is called a glycoprotein F, and it's designed to trigger your immune system to recognize and fight RSV if you encounter the actual virus later. This type of vaccine technology has been used for decades in other vaccines, making it a well-established approach.

Abrysvo uses messenger RNA, or mRNA, technology—the same approach used in some COVID-19 vaccines. The vaccine contains genetic instructions that tell your cells to make a piece of the RSV protein. Your immune system then responds to this protein. The advantage of mRNA vaccines is that they can be produced relatively quickly and don't require growing proteins in cell cultures, but this was a newer technology for most people when COVID vaccines rolled out.

Both vaccines showed strong effectiveness in clinical trials. Arexvy demonstrated approximately 94% effectiveness at preventing severe RSV disease in adults aged 60 and older. Abrysvo showed approximately 82% effectiveness in adults aged 60 and older, and notably higher effectiveness (94%) in adults aged 75 and older. These numbers come from large randomized controlled trials involving thousands of participants followed for months to track RSV infections.

The side effect profiles are similar for both vaccines. Common reactions include arm soreness at the injection site, fatigue, muscle aches, and headache—the same kinds of reactions people experience with flu shots. These typically resolve within a few days. Serious allergic reactions are rare but possible, as with any vaccine.

One practical difference involves availability and administration. Different healthcare settings may stock one vaccine or the other, though both are now distributed through standard pharmacy and medical office channels. If you have a strong preference based on the technology used or other factors, you can discuss this with your healthcare provider, though they may not have a choice about which vaccine is available at their location.

Practical takeaway: Both vaccines use proven safety technology and show strong protection. The choice between them may depend more on what your doctor has available than on major differences in how they work or how safe they are.

Who Should Get the RSV Vaccine: Understanding Recommendations

This is where the RSV vaccine landscape gets somewhat more complicated than vaccines you may be more familiar with. Unlike the flu vaccine, which is recommended for nearly all adults, or the updated COVID vaccine, which has broad recommendations, RSV vaccine guidance distinguishes between different groups of older adults based on their individual risk level.

Get Your Free OnStar Pricing and Features Guide →

The CDC's Advisory Committee on Immunization Practices (ACIP) provided guidance in 2023 that divides recommendations into three categories: shared clinical decision-making, routine recommendations, and specific recommendations.

For adults aged 60 to 74 with no chronic conditions or risk factors, the CDC recommends shared clinical decision-making. This means you and your healthcare provider should discuss your individual situation together to decide if the vaccine makes sense for you. The conversation might explore whether you live with young grandchildren who could bring RSV home, whether you spend time in group settings, whether you travel frequently, or whether you have concerns about RSV risk. This isn't a straightforward "yes, get it" or "no, don't"—it's a discussion tailored to your life.

For adults aged 60 and older with chronic conditions, the recommendation shifts toward routine vaccination. Chronic conditions that increase RSV risk include chronic obstructive pulmonary disease (COPD), chronic heart disease, asthma, diabetes, and immunocompromising conditions. If you fall into this group, your healthcare provider will typically recommend the vaccine as a standard preventive measure, similar to how they'd recommend the flu shot.

For all adults aged 75 and older, the CDC recommends routine vaccination regardless of health status. At this age, the biological changes that come with aging itself create enough additional risk that vaccination is recommended across the board.

Additionally, the vaccine is recommended for adults of any age living in group settings like nursing homes, assisted living facilities, or long-term care communities. The concentrated population in these settings means RSV can spread rapidly, affecting vulnerable people in close quarters.

It's important to note that these are recommendations, not mandates. No one is required to get the RSV vaccine, and no facility can legally force you to receive it. These recommendations reflect the CDC's assessment of where the vaccine provides the most public health benefit based on research data.

Your individual medical history matters significantly. If you've had a severe allergic reaction to any vaccine component, or if you have a condition that affects how you respond to vaccines, your doctor may advise against it. Similarly, if you had RSV recently, you might wait a certain period before getting vaccinated, though vaccination is still recommended eventually.

Practical takeaway: Unlike some vaccines with blanket recommendations, RSV vaccine advice depends on your age and health. If you're under 75 and healthy, the decision involves a conversation with your doctor. If you're 75 or older, or have chronic health conditions, vaccination is typically recommended.

The Clinical Trial Evidence: What the Numbers Show

Understanding how well the RSV vaccines actually work means looking at the research that led to their approval. This wasn't a quick process—both vaccines were tested in large, long-term studies involving thousands of older adults before reaching the market.

Learn About Victoria's Secret Credit Card Online Access →

The Arexvy trials included over 32,000 adults aged 60 and older across multiple countries. Researchers followed these participants for a year, tracking who developed RSV infection and how severe it was. Among vaccinated people, severe RSV disease occurred in approximately 0.7 per 1,000 people over the year. Among unvaccinated people in the placebo group, the rate was about 12 per 1,000. This translates to a 94% reduction in severe disease risk—meaning the vaccine prevented about 94 out of every 100 cases of serious RSV illness that would otherwise have occurred in the vaccinated group.